Status:

TERMINATED

The Effect of Chronic Pain on Delay Discounting in Methadone Patients

Lead Sponsor:

University of California, San Francisco

Collaborating Sponsors:

Johns Hopkins University

National Institute on Drug Abuse (NIDA)

Conditions:

Opioid-use Disorder

Chronic Pain Syndrome

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

Brief Summary

The epidemic of opioid overdose deaths continues to rise, killing more persons in 2017 than HIV/AIDS at the height of that epidemic. Medication assisted treatment, including methadone and buprenorphin...

Detailed Description

This is an outpatient Phase 1 clinical trial investigating the effect of naloxone precipitated withdrawal on delay discounting. Eligible participants will undergo two experimental sessions presented i...

Eligibility Criteria

Inclusion

  • Male and female adults aged 18-65
  • Stable methadone dose (at least 21 days) verified by contacting participant's opioid treatment program
  • Understand and speak English
  • Urine toxicology screen negative for drugs of abuse and positive for methadone
  • Participants must be without signs of intoxication as evidenced by ability to receive full dose of methadone prior to research activities.
  • Presence of chronic pain (\>3 months) for the Pain group and absence of pain for the No Pain group.

Exclusion

  • Unstable psychiatric illness as assessed by the Mini International Neuropsychiatric Interview (e.g. active suicidal ideation, psychosis)
  • Unstable medical illness as assessed by the study's independent medical monitor (e.g. uncontrolled hypertension, recent myocardial infarction, recent stroke, unstable angina) that may be affected by precipitated withdrawal
  • Prescription opioid use besides methadone
  • Acute pain process unrelated to chronic pain
  • Women who are pregnant or lactating
  • Known allergy to naloxone

Key Trial Info

Start Date :

January 8 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 6 2022

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT04473950

Start Date

January 8 2020

End Date

October 6 2022

Last Update

March 26 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Zuckerberg San Francisco General Hospital

San Francisco, California, United States, 94110